Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon Raises $5M

NEW YORK (GenomeWeb) – Metabolon has raised $5 million in an extension of its Series E financing round. 

The Durham, NC-based metabolomics firm disclosed the financing in a regulatory document filed with the US Securities and Exchange Commission on Thursday. A company spokesperson told GenomeWeb that the financing is an extension of the Series E round completed in January 2014 that brought in $15 million in a preferred stock offering and brings the total amount raised in the round to $20 million.

The proceeds will be used for general working purposes. According to the SEC document, four investors participated in the current financing, though the company spokesperson declined to identify them. Investors in the 2014 financing included Camden Partners, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght, Fulcrum Financial Partners, and Sumitomo. 

The company's metabolomics-based platform is used for biomarker discovery and developing diagnostic tests for obesity-related diseases. Metabolon also markets laboratory-developed tests for monitoring patients who are at risk for developing diabetes and helping clinicians make treatment decisions.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.